Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Genedrive PLC

GDR.L ✓ COMPLIANTFree checks used up today ☆ Track — members

LSE · Healthcare · Advanced Medical Equipment & Technology ·

UK Micro Cap Analyst: N/A

Last Close

$0.01

▼ -2.27%

Market Cap $22.79M · Vol 3.53M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$22.79M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

22.22

Momentum

Beta

3.20

vs Market

52W High

$0.02

31.99% below

52W Low

$0.00

284.09% above

Volume

3.53M

Avg 3.73M

P/B

6.08

Price-to-book

ROE

N/A

Return on equity

Free Float

54.73%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Genedrive PLC (GDR.L) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GDR.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.51%

-17.31%

-8.51%

+16.22%

YTD

+24.29%

+219.87%

-85.16%

-93.96%

Financials & Valuation

TTM · Annual

Total Revenue	$1.31M
Net Income	$-7,183,762.00
Revenue Growth (YoY)	+62.86%
Gross Margin	100.00%
Operating Margin	-563.94%
Net Profit Margin	-548.32%
ROE	N/A
ROA · ROIC	-112.87% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	8.26
P/B	6.08
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.61B

Technical Indicators

50-Day SMA	$0.02
200-Day SMA	$0.01
RSI (14)	22.22
Beta	3.20
52-Week High	$0.02
52-Week Low	$0.00

Volume Today	3.53M
Avg Daily Volume (30D)	3.73M
Relative Volume	0.95x
Volatility (10D)	27.67
Volatility (30D)	32.47
Free Float	54.73%

Analyst Consensus

N/A

Current Price $0.01

Mean Target N/A

52W Low$0.00 52W High$0.02

Current

Target

$0.00 $0.02

Current Analyst target

· 0 analysts

Identifiers

ExchangeLSE

FIGIBBG001SS3PR7

ISINGB00B1VKB244

CountryUK

Sub-IndustryMedical Diagnostic & Testing Equipment

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

SRT.DE Sartorius AG -0.74% BIOT.ST Biotage AB +0.14% EUZ.DE Eckert & Ziegler SE +0.24% VREX Varex Imaging Corporation -0.05% CEVI.ST CellaVision AB +1.59%

Company Profile

genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.